Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS BioSpaceBiogen's Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.NeuroscienceRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioSpace Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beatNext: Viridian data lift prospects for thyroid eye disease drug Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
